Glucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults. However, despite this rapid adoption and the known GLP-1RA mechanism of action for weight loss, which targets brain circuits responsible for appetite and eating behaviors, almost nothing is known about how these drugs affect the brain in youth who are treated for obesity, or how these drugs affect the brain of youth differently from adults. The goal of the current study is to compare youth and adults with obesity who are treated a GLP-1RA and measure potential difference in GLP-1RA associated change in brain function, appetite, and eating behaviors.

Start Date01 May 2026

Sponsor / Collaborator

University of Colorado Denver

[+1]

NCT07179120

/ Not yet recruitingPhase 2IIT

Male Fertility Preservation: Efficacy Evaluation of GLP-1Receptor Agonist Therapy for Infertility in Obese Males - A Multicenter Clinical Randomized Controlled Trial

Why is this study being done? Obesity can harm men's fertility by lowering sperm quality and hormone levels, making it harder to have children. Weight loss through diet and exercise helps, but it's often hard to stick with. New medicines called GLP-1 receptor agonists, like semaglutide (Ozempic) and tirzepatide (Mounjaro), help people lose weight and improve health. Early studies suggest these drugs might also boost sperm health in obese men, but more proof is needed. This study tests if these drugs can safely improve fertility in obese men who are having trouble conceiving.
What will happen in this study?
This is a 48-week study at several hospitals in China. About 180 men will be randomly assigned to one of three groups:
Group 1: Standard lifestyle changes, like a healthy diet and exercise, guided by experts.
Group 2: Weekly injections of semaglutide, starting low and increasing as tolerated.
Group 3: Weekly injections of tirzepatide, starting low and increasing as tolerated.
All men will have regular check-ups, including blood tests, semen analysis, and weight measurements. We will track sperm quality, hormone levels, weight loss, and whether their partners get pregnant naturally. The study includes an 8-week adjustment period, 24 weeks of treatment, and 16 weeks of follow-up.
Who can join this study? Men aged 20-45 who are married, obese (BMI 28 or higher or waist size 90 cm or more), and have been trying to have a baby for at least a year without success due to low sperm count or poor sperm movement. Their female partners must be under 40 and have no major fertility issues. Men must be willing to attend visits and provide samples. People with serious health problems, recent use of similar drugs, or other causes of infertility (like genetic issues) cannot join.
How long will this study last? The full study lasts 48 weeks (about 11 months), with visits every 4-8 weeks, plus monthly phone check-ins for pregnancy updates.
What are the possible benefits and risks? Benefits: If the drugs work, men may lose weight, improve sperm quality, and have a better chance of their partners getting pregnant naturally. They might also feel healthier overall. Risks: Common side effects include nausea, vomiting, or diarrhea from the drugs, which usually improve over time. Rare risks include pancreas inflammation or gallbladder issues. Lifestyle changes might cause minor injuries from exercise. All side effects will be monitored closely, and participants can quit anytime. Insurance covers any study-related harm.

Start Date01 May 2026

Sponsor / Collaborator

The First Affiliated Hospital of Wenzhou Medical College

NCT07090343

/ Not yet recruitingPhase 3IIT

Semaglutide for Reducing Cardiovascular Events in Patients Undergoing Transcatether Aortic Valve Replacement

This is a Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial evaluating the safety and efficacy of once-weekly semaglutide 2.4 mg in adult patients undergoing transcatheter aortic valve replacement (TAVR) for severe aortic stenosis (AS) who meet current clinical criteria for semaglutide treatment. A total of 826 participants will be randomized 1:1 to receive semaglutide or placebo as an add-on to standard-of-care, starting 3 months before TAVR and continuing for 24 months post-procedure. The primary endpoint is time to first occurrence of a composite of cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke or transient ischemic accident (TIA), and hospitalization for heart failure (HF). The study is event-driven and powered to detect a 20% relative risk reduction in primary outcome events. This trial aims to address the unmet need for medical therapies that improve outcomes in patients with severe AS following TAVR, with potential for direct clinical implementation.

Start Date01 Apr 2026

Sponsor / Collaborator

Leids Universitair Medisch Centrum

100 Clinical Results associated with Semaglutide (Novo Nordisk)

100 Translational Medicine associated with Semaglutide (Novo Nordisk)

100 Patents (Medical) associated with Semaglutide (Novo Nordisk)

334

Literatures (Medical) associated with Semaglutide (Novo Nordisk)

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Impact of semaglutide 2.4 mg on healthcare resource utilization and medical costs in patients with atherosclerotic cardiovascular disease in the United States (SHINE-ASCVD)

Article

Author: Zhao, Zhenxiang ; Alvarez, Sara ; Michalak, Wojciech ; Faurby, Mads ; Fitch, Angela

BACKGROUND:

Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality. Semaglutide 2.4 mg (Wegovy) has demonstrated improved outcomes in patients with overweight or obesity (ov/ob) and ASCVD, but its impact on medical costs and healthcare resource utilization (HCRU) remains unknown.

AIMS:

To compare all-cause medical costs and HCRU among patients with ov/ob and ASCVD treated with semaglutide 2.4 mg versus semaglutide-untreated controls.

MATERIALS AND METHODS:

This observational cohort study utilized Komodo's Healthcare Map and included patients with ov/ob and ≥1 diagnosis of ASCVD during the baseline period with ≥12 months of insurance coverage before and after the index date. Patients in the semaglutide 2.4 mg cohort initiated treatment after 4 June 2021 and stayed adherent. Semaglutide-untreated controls were randomly selected and 1:4 propensity score matched based on baseline demographics, clinical characteristics, medical costs, and HCRU. Medical costs and HCRU were compared using generalized linear models.

RESULTS:

770 semaglutide 2.4 mg-treated patients and 3,080 controls were included. In the year following treatment initiation, semaglutide 2.4 mg was associated with 22% lower mean medical costs versus controls (-$4,639 per patient per year [PPPY]; cost ratio = 0.78, 95% confidence interval [CI] 0.67, 0.89). This difference is mainly due to lower inpatient costs with semaglutide 2.4 mg, which were 65% lower than controls (-$3,593; cost ratio = 0.35 [95% CI 0.21, 0.49]), along with a 48% lower inpatient visit rate (0.08 vs. 0.15; rate ratio = 0.52 [95% CI 0.34, 0.70]).

LIMITATIONS:

Limitations inherent to retrospective claims analyses apply to this study.

CONCLUSIONS:

This real-world analysis shows significantly lower annual medical costs and HCRU with semaglutide 2.4 mg versus no semaglutide 2.4 mg treatment in patients with ov/ob and ASCVD. Improving outcomes with semaglutide 2.4 mg combined with lower costs and HCRU may help slow the growing burden of ASCVD in this population.

01 Dec 2025·NEUROPHARMACOLOGY

GLP-1 receptor agonist semaglutide ameliorates motor deficits and tau pathology in the rTg4510s mouse model

Article

Author: Li, Xin-Yi ; Liu, Feng-Tao ; Xu, Zhi-Heng ; Lin, Hua-Mei ; Zhang, Meng-Wei ; Chen, Chen ; Zuo, Chuan-Tao ; Wu, Jian-Jun ; Zhao, Jue ; Wang, Jian ; Yu, Wen-Bo ; Tang, Yi-Lin ; Zhou, Wan-Yi ; Sun, Yi-Min

BACKGROUND:

Tauopathies, including Alzheimer's disease, are characterized by progressive neurodegeneration manifesting as motor and cognitive impairments. This study evaluated the therapeutic potential of semaglutide, a clinically approved glucagon-like peptide-1 receptor agonist, in the rTg4510 mouse model of tauopathy.

METHODS:

Starting at three months of age, rTg4510 mice and wild-type littermates received semaglutide (0.10 mg kg^-1, intraperitoneal) or vehicle (PBS) every other day for 16 weeks. Motor coordination, anxiety-like behavior, spatial working memory, and associative fear memory were assessed using behavioral paradigms. Tau accumulation was monitored via 18F-PM-PBB3 micro-PET/CT imaging. Immunohistochemistry and immunoblot analyses quantified tau pathology, neuronal integrity, and glial activation.

RESULTS:

Semaglutide significantly improved motor coordination in rTg4510 mice on the pole test, though not rotarod endurance. While spontaneous locomotion, anxiety-like behaviors, and Y-maze spatial working memory remained unchanged, semaglutide significantly enhanced cue-dependent freezing in fear conditioning, indicating improved associative memory. ¹⁸F-PM-PBB3 PET imaging revealed a pronounced reduction in cortical and hippocampal tracer uptake, indicative of reduced tau burden. Immunohistochemistry and Western blotting confirmed significantly decreased cortical phosphorylated tau (AT8) levels. Semaglutide preserved cortical neuronal integrity; however, no hippocampal changes were detected, likely due to minimal baseline neuron loss at this age. Astrocytic (GFAP) and microglial (Iba1) activation remained unaffected.

CONCLUSION:

Semaglutide ameliorated domain-specific motor impairments, enhanced associative fear memory, and attenuated cortical tau pathology in rTg4510 mice. These findings highlight therapeutic promise of semaglutide as a disease-modifying agent for tauopathies, justifying further dose-response, mechanistic, and translational studies.

01 Dec 2025·SOCIAL SCIENCE & MEDICINE

Even with diet and exercise, Ozempic use reduces perceived effort and praiseworthiness of resulting weight loss

Article

Author: Savulescu, Julian ; Dranseika, Vilius ; Devolder, Katrien ; Hannikainen, Ivar ; Brown, Rebecca C H ; Earp, Brian D ; Ryan, Nanette ; Everett, Jim A C ; Buyukbabani, Mey Bahar ; Bachmakova, Maria

The injectable medication Ozempic (semaglutide) has demonstrated unprecedented effectiveness in promoting significant weight loss. However, its use has sparked moral debates, with critics dismissing it as a mere "shortcut" compared to traditional methods like diet and exercise. This study investigates how weight loss method-Ozempic, diet/exercise, or a combination of both-impacts perceptions of effort, praiseworthiness, and identity/value change. We used a contrastive vignette technique in two experiments (combined N = 1041, demographically representative for age, sex, and ethnicity) to study the attitudes of US participants toward a fictional character who lost 50 pounds through one of the three described methods. Weight loss through diet/exercise alone was deemed most effortful and most praiseworthy, whereas Ozempic use, even when combined with diet/exercise, was rated as both less effortful and less praiseworthy than diet/exercise alone. Ozempic use with no mention of diet/exercise was rated as least effortful and least praiseworthy. Compared to diet and exercise alone, Ozempic use also decreased perceptions that the individual had really changed as a person, or experienced a change in their underlying values. We discuss potential implications, address study limitations, and provide suggestions for further work.

2,398

News (Medical) associated with Semaglutide (Novo Nordisk)

23 Oct 2025

·endpoints.news

Ventyx's stock soars on cardiovascular data for NLRP3 drug

Ventyx Biosciences’ Phase 2 data showed a significant reduction in cardiovascular risks in patients with obesity through NLRP3 inhibition, a closely-watched target in neurologic and cardiometabolic drug development. After the readout was announced on Wednesday, the biotech’s stock $VTYX was up more than 85% on Thursday morning. That said, the future of VTX3232 could hinge on the ambitions of Sanofi, which paid $27 million in September 2024 to snag the rights to first negotiation for the once-daily oral NLRP3 inhibitor. Sanofi has acted on similar rights, having bought Vigil Neuroscience earlier this year after getting the negotiation rights to the biotech’s Alzheimer’s disease drug in 2024. “This is the first time we’re publicly disclosing this data, so [Sanofi] has not had a chance to see it. I’m hoping some of them have seen it today,” Ventyx CEO Raju Mohan said Wednesday during an analyst call. It’s unclear how long Sanofi gets to “review the results and determine if they have an interest in the molecule,” according to a Stifel note. A Sanofi spokesperson didn’t respond to a request for comment. The company is scheduled to report its third-quarter results on Friday. “Ultimately, NLRP3 could be a high-value target for big pharma,” Jefferies analysts wrote in a note. NLRP3 inhibitors tamp down on inflammation to lower cardiovascular risks, but they may also have the potential to treat neurological disorders. VTX3232 has completed a Phase 2 biomarker trial in patients with early forms of Parkinson’s disease. The target has attracted the interest of both drug giants and small biotechs working in cardiometabolic and neurologic R&D. That includes Novo Nordisk-partnered Ventus Therapeutics , Tenvie and NodThera , which is backed by Sanofi Ventures. Roche is also working on a Phase 1b oral candidate called selnoflast from its acquisition of Inflazome in 2020 for $448 million upfront. In the Phase 2 trial results, Ventyx said VTX3232 led to “significant reductions” in cardiovascular disease threats. The trial tested the experimental medicine alone and in combination with Novo Nordisk’s GLP-1 semaglutide. The primary endpoint of the trial was safety and tolerability. Ventyx said rates of adverse events for patients on its drug were “comparable to placebo.” On the key secondary endpoint, looking at inflammation, patients taking VTX3232 had a 64% reduction in high-sensitivity C-reactive protein (hsCRP) in the “full analysis set” at week 12 relative to baseline. There was a 3% increase in that measure in the placebo group. The p-value came in at p<0.0001. Meanwhile, the drug also led to statistically significant drops in lipoprotein(a) and liver inflammation, and it helped move interleukin-6 levels below the threshold for cardiovascular risk, according to Ventyx. The drug did not lead to weight loss, either as a single agent or in combination with semaglutide. The data are “now showing conclusively that NLRP3 inhibition has no effect in humans in promoting weight loss,” Mohan said on the call. Stifel analysts said it was “puzzling” that there was no effect on weight, given the signals in mouse models. But “the impact on biomarkers could support a path forward” for the drug in reducing cardiovascular risks, they wrote. Novartis bet $1.4 billion last month to get an anti-IL-6 drug via its acquisition of Tourmaline Bio , and Novo is also developing an IL-6 called ziltivekimab, which is in Phase 3 trials . “The potential for an ‘oral IL-6’ clearly has wide-ranging potential across a range of CV diseases with ongoing outcomes studies expected over the 2026/27 timeframe for Novo’s ziltivekimab, which represents a meaningful datapoint for the space,” the Stifel analysts wrote.

AcquisitionClinical ResultPhase 2Phase 3AHA

23 Oct 2025

·firstwordpharma.com

ICER finds new drug launches keep getting pricier and harder to access

Drug launch prices in the US continue to rise sharply, outpacing inflation, economic growth and overall healthcare costs, according to a new analysis from the Institute for Clinical and Economic Review (ICER) released Thursday."Launch prices are going up, patient access is going down, and in many cases, we are overpaying for treatments," said CEO Sarah Emond. "As Americans confront rising health insurance premiums and risk losing health insurance altogether, it has never been more critical to move towards a system that pays for value."Jump of 51%The watchdog's inaugural Launch Price and Access Report analysed 154 novel drugs approved by the FDA from 2022 to 2024 and found that median annual launch prices, adjusted for inflation, jumped 51% over that period, while list prices rose 24%.Even after adjusting for the types of drugs launched each year, ICER said net prices rose 33% annually — a trend that held even when researchers controlled for the mix of medicines entering the market, ruling out the possibility that spikes were simply due to more gene therapies or innovative treatments winning approvals.Further, of the 23 drugs previously reviewed by ICER, 16 were priced above the watchdog's upper-bound Health Benefit Price Benchmark — a value-based range that ICER considers a fair reflection of a medince's lifetime health benefits at the time of approval.Some of the largest gaps were found for Merck & Co.'s pulmonary hypertension therapy Winrevair (sotatercept), which would have needed discounts of up to 91% to meet value thresholds, followed by Bridgebio's heart drug Attruby (acoramidis), Bristol Myers Squibb's cardiomyopathy medicine Camzyos (mavacamten), and the amyotrophic lateral sclerosis drug Relyvrio (sodium phenylbutyrate and taurursodiol), which was ultimately withdrawn by Amylyx Pharmaceuticals after it failed a confirmatory study.In total, pricing discrepancies for those 16 drugs led to between $1.3 billion and $1.5 billion in first-year excess spending, according to the report.Coverage gapsFurther, the report identified major gaps in coverage and delayed insurance access for new therapies. Among drugs approved in 2024, ICER found that most lacked public coverage policies even a year after approval. Prescription data showed that over half of new-to-brand prescriptions were rejected, and only 29% were ultimately filled. Non-coverage was the most common reason for rejection, often as a result of a "new-to-market block" on insurance coverage."Although, in principle, these blocks can be justified to allow an insurer adequate time to review the clinical evidence, the lack of timely coverage policies could limit or delay access… Thus, we emphasise the need for early evidence evaluation by payers and the importance of early data sharing by drugmakers to enhance patient access," ICER said.Zepbound singled outMeanwhile, given the popularity of GLP-1 treatments, the analysis also singled out Eli Lilly's blockbuster obesity treatment Zepbound (tirzepatide) as a special case, saying it "raises questions about how best to structure coverage to maintain access and affordability for high-value drugs such as GLP-1s, which have a large eligible population."Despite GLP-1s being deemed cost-effective by ICER at current prices, Thursday's report found that only 34% of new Zepbound prescriptions were filled in early 2025, while 62% were rejected, primarily due to coverage restrictions and prior authorisation/step therapy barriers. ICER noted that the results are likely representative of Novo Nordisk's weight-loss drug Wegovy (semaglutide) as well.

23 Oct 2025

·firstwordpharma.com

Ventyx's NLRP3 inhibitor drastically lowers CV risk markers, shares skyrocket

Sanofi is presumably patting itself on the back now that a programme it bet on last year has produced promising cardiovascular (CV) risk-reduction results in a mid-stage study. The French drugmaker put up $27 million in 2024 for the right of first negotiation to VTX3232, an oral, once-daily NLRP3 inhibitor being developed by Ventyx Biosciences for patients with Parkinson's disease, and those with obesity (see – Vital Signs: Pharma pushes toward non-incretin alternatives in obesity).And while Phase II obesity data, reported by Ventyx late on Wednesday, showed that VTX3232 didn't help patients lose weight, the candidate had a compelling effect on biomarkers associated with inflammation and CV risk. The results sent Ventyx's shares soaring about 90% on Thursday. Biomarker resultsThe 175-patient study enrolled individuals with a BMI between 30 and 42 kg/m2 who were at risk for CV disease, as determined by a high-sensitivity C-reactive protein (hsCRP) measurement of ≥2 mg/L at screening. Studies suggest the biomarker "strongly predicts" future CV events, according to Peter Libby, a CV specialist at Mass General Brigham Heart & Vascular Institute. Patients were randomised to take VTX3232 or placebo alone, or either in combination with Novo Nordisk's GLP-1 agonist semaglutide.After 12 weeks, those who received at least one dose of the NLRP3 inhibitor monotherapy saw a 64% reduction from baseline in hsCRP, while the placebo group had a 3% increase. In a modified analysis set that excluded participants who had no detectable VTX3232 plasma levels at week 12, the degree of hsCRP reduction jumped to 78%. Both results were statistically significant, meeting the study's secondary endpoint. "The robust CRP-lowering possible with novel agents such as NLRP3 inhibitors offers new options for anti-inflammatory therapies to treat atherosclerosis and prevent its complications that add to the established benefits of cholesterol-lowering therapies," said Libby.Furthermore, patients in the VTX3232 monotherapy arm experienced statistically significant reductions in Lp(a), fibrinogen, erythrocyte sedimentation rate (ESR) and liver inflammation. The candidate lowered IL-6 to median levels of 1.60 ng/L, below the threshold for CV risk of ≤1.65 ng/L. Ventyx reported that in the combination arm, the addition of VTX3232 led to significant reductions in hsCRP, IL-6, fibrogen, ESR, Lp(a) and liver inflammation over semaglutide alone."The effect we see in this study on…markers of aberrant systemic inflammation leads us to believe VTX3232 holds promise for a new generation of oral anti-inflammatory therapies that, orthogonal to lipid lowering, may further reduce the risk of cardiovascular events," said Ventyx CEO Raju Mohan.On the primary safety endpoint, the candidate was also well-tolerated with rates of adverse events comparable to placebo. Ventyx plans to present additional data from the Phase II study at upcoming medical conferences.

Clinical ResultPhase 2AHA

100 Deals associated with Semaglutide (Novo Nordisk)

External Link

KEGG	Wiki	ATC	Drug Bank
D10025	Semaglutide (Novo Nordisk)	A10BJ06	DB13928

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cardiovascular Diseases	United States	Novo Nordisk, Inc.	15 Aug 2025
Metabolic Dysfunction Associated Steatohepatitis	United States	Novo Nordisk A/S	15 Aug 2025
Metabolic Dysfunction Associated Steatohepatitis	United States	Novo Nordisk, Inc.	15 Aug 2025
Chronic Kidney Diseases	United States	Novo Nordisk, Inc.	28 Jan 2025
Chronic Kidney Diseases	United States	Novo Nordisk A/S	28 Jan 2025
Stroke	Australia	Novo Nordisk Pharmaceuticals Pty Ltd.	16 Dec 2024
Myocardial Infarction	Canada	Novo Nordisk Canada, Inc.	27 Nov 2024
Obesity	United States	Novo Nordisk, Inc.	04 Jun 2021
Overweight	United States	Novo Nordisk, Inc.	04 Jun 2021
Diabetes Mellitus, Type 2	United States	Novo Nordisk, Inc.	05 Dec 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Albuminuria	Phase 3	Canada	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Germany	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Netherlands	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Spain	Novo Nordisk A/S	14 Mar 2022
Osteoarthritis, Knee	Phase 3	United States	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Canada	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Colombia	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Denmark	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	France	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Norway	Novo Nordisk A/S	01 Oct 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03574597 (SELECT, Pubmed \| J Med Econ)	Phase 3	Cardiovascular Diseases \| Obesity	-	Semaglutide 2.4 mg	hffpspbhdd(jlsohflnzh) = iyddxnnnee lvonjwflxs (kyqovfbtxg ) View more	Positive	31 Dec 2025
NCT04916470 (STEP-HFpEF DM, Pubmed \| JACC Heart Fail)	Phase 3	-	1,145	Semaglutide	zrniwmnayr(axeamugxdl): Difference (Semaglutide vs Placebo) = 14.6 (95.0% CI, 8.6 - 20.7), P-Value = < 0.0001 View more	Positive	01 Nov 2025
				Placebo
NCT06914141 \| NCT06914154 \| NCT06914102 (Pubmed \| JAMA)	Not Applicable	Heart failure with normal ejection fraction	97,790	Semaglutide	iqmuexarse(wnwsmkyubf): HR = 0.58 (95.0% CI, 0.51 - 0.65) View more	Positive	14 Oct 2025
				Tirzepatide
NCT02970942 \| NCT03552757 \| NCT03548935 (STEP 1, Pubmed \| JHEP Rep)	Phase 2	Metabolic Dysfunction Associated Steatohepatitis	-	Semaglutide 2.4 mg	rwisaszrkf(tbeuehpdsf) = mekscgsmba gvxtxaryps (lxreeomfbk ) View more	Positive	01 Oct 2025
				Semaglutide 1.0 mg	rwisaszrkf(tbeuehpdsf) = qvukndntub gvxtxaryps (lxreeomfbk ) View more
NCT03914326 (SOUL, CTgov)	Phase 3	Diabetes Mellitus, Type 2 \| Myocardial Infarction \| Heart Diseases ... View more	9,651	Semaglutide (Oral Semaglutide)	izlootoecm = nlwadptltg lcpcbzmuru (zsendvpudb, rwwuqetrnc - xyazuqznqk) View more	-	22 Sep 2025
				Placebo (semaglutide) (Placebo)	izlootoecm = oidyucknph lcpcbzmuru (zsendvpudb, jfdvgdaiqe - kjvvuevtfm) View more
NCT05564117 (OASIS 4, Pubmed \| N Engl J Med)	Phase 3	-	307	Oral Semaglutide 25 mg	dmxptfjidx(ihwwljpjzh) = tfqpylrspp csvhmfsmui (aodonlfmwk )	Positive	18 Sep 2025
				Placebo	dmxptfjidx(ihwwljpjzh) = smwiifyivh csvhmfsmui (aodonlfmwk )
NCT04126603 (CTgov)	Phase 4	Diabetes Mellitus, Type 2	10	Placebos (Group A Placebo)	dzsmhthcds(ahyobueypx) = conxyegkfw nptcgvvkby (hkfrvpgtuf, 0.06) View more	-	09 Sep 2025
				Semaglutide (Group B Active)	dzsmhthcds(ahyobueypx) = payfpcuztc nptcgvvkby (hkfrvpgtuf, 0.16) View more
NCT05193578 (Pubmed \| JAMA Psychiatry)	Phase 3	Schizophrenia	154	Semaglutide	inyclljplr(rlrpbleasd) = kmneouuqxg dkeyynadfg (kkqfjordsz, 1.52 - 5.98) View more	Positive	03 Sep 2025
STEER (PRNewswire \| NEWS) Manual	Not Applicable	Obesity	-	Wegovy 2.4 mg	hrpmdfbtgm(umvumpsxqa) = Wegovy showed a significant 29% risk reduction compared with tirzepatide. jwjrjgfwzn (fxjljikifr ) View more	Positive	01 Sep 2025
				Tirzepatide
NCT03596450 (SEMAPRA, Pubmed) Manual	Phase 4	Diabetes Mellitus, Type 2	1,278	Semaglutide	xjdwechntr(waaigtplae) = bwhlqxqzyx nicvgwzmpz (wunkblifer ) View more	Positive	01 Sep 2025
				Standard of care	xjdwechntr(waaigtplae) = kzupnzepbt nicvgwzmpz (wunkblifer ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis